医学
间充质干细胞
外科
腰椎
腰痛
退行性椎间盘病
骨髓
随机对照试验
椎间盘
磁共振成像
临床试验
病理
放射科
替代医学
作者
David C. Noriega,Francisco Ardura,Rubén Hernández-Ramajo,Miguel Ángel Martín-Ferrero,Israel Sánchez‐Lite,Borja Toribio,Mercedes Alberca,Verónica García,José María Moraleda,Abraham Sánchez,Javier García‐Sancho
出处
期刊:Transplantation
[Ovid Technologies (Wolters Kluwer)]
日期:2017-08-01
卷期号:101 (8): 1945-1951
被引量:180
标识
DOI:10.1097/tp.0000000000001484
摘要
In Brief Background Degenerative disc disease often causes severe low-back pain, a public health problem with huge economic and life quality impact. Chronic cases often require surgery, which may lead to biomechanical problems and accelerated degeneration of the adjacent segments. Autologous mesenchymal stromal cells (MSC) treatments have shown feasibility, safety and strong indications of clinical efficacy. We present here a randomized, controlled trial using allogeneic MSC, which are logistically more convenient than autologous cells. Methods We randomized 24 patients with chronic back pain diagnosed with lumbar disk degeneration and unresponsive to conservative treatments into 2 groups. The test group received allogeneic bone marrow MSCs by intradiscal injection of 25 × 106 cells per segment under local anesthesia. The control group received a sham infiltration of paravertebral musculature with the anesthetic. Clinical outcomes were followed up for 1 year and included evaluation of pain, disability, and quality of life. Disc quality was followed up by magnetic resonance imaging. Results Feasibility and safety were confirmed and indications of clinical efficacy were identified. MSC-treated patients displayed a quick and significant improvement in algofunctional indices versus the controls. This improvement seemed restricted to a group of responders that included 40% of the cohort. Degeneration, quantified by Pfirrmann grading, improved in the MSC-treated patients and worsened in the controls. Conclusions Allogeneic MSC therapy may be a valid alternative for the treatment of degenerative disc disease that is more logistically convenient than the autologous MSC treatment. The intervention is simple, does not require surgery, provides pain relief, and significantly improves disc quality. Injection of autologous mesenchymal stromal cells (MSC) is used to treat intervertebral disc disease. This randomized, sham-controlled, study shows that injection of allogeneic MSC, which is easier logistically, produces immediate pain relief and improvement in disc degeneration.
科研通智能强力驱动
Strongly Powered by AbleSci AI